Question Over Ramucirumab in First-Line Gastric Cancer Question Over Ramucirumab in First-Line Gastric Cancer
In combination with chemotherapy, ramucirumab improved progression-free survival but not overall survival or response rate in advanced gastric or gastroesophageal junction cancers.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Gastric (Stomach) Cancer | Gastroenterology | Health | Hematology